PharmNovo in Näringsliv
PharmNovo is featured in an article in the business magazine Affärstidningen Näringsliv. Bengt von Mentzer, Founder of PharmNovo, and Per von Mentzer, CEO of PharmNovo, tell the story of our company and our vision to change the lives of people suffering from chronic neuropathic pain.
PharmNovo in Näringsliv
PharmNovo is featured in an article in the business magazine Affärstidningen Näringsliv. Bengt von Mentzer, Founder of PharmNovo, and Per von Mentzer, CEO of PharmNovo, tell the story of our company and our vision to change the lives of people suffering from chronic neuropathic pain.
Latest news
View all
PharmNovo at the LSX Nordic Congress
PharmNovo attended the LSX Nordic Congress in Copenhagen 8-9 October and Per von Mentzer, CEO presented PN6047, a unique first-in-class phase II ready asset with break-through potential in treatment of neuropathic pain. Being one of 68 companies that have recently been awarded by EIC for up to 17.5 MEUR (2.5 MEUR grant and up to 15 MEUR equity) from a total of 969 applicants is a strong validation of the potential of the phase II ready asset PN6047 and of PharmNovo. Take the opportunity to listen to the presentation here:
Read more
17.5 MEUR blended funding from EIC
PharmNovo is very pleased to announce that we have been awarded a 2.5 MEUR grant and an opportunity for up to 15 MEUR equity investment from the European Innovation Council (EIC) for innovative pain treatment. The equity part being contingent on investments of equal amounts from co-investors.
Read more
PharmNovo presenting at the Global Forum
On May 29–30, BioStock hosted the Global Forum. The event is the first of its kind, aimed at bringing together growth stage Nordic life science companies looking to expand into new markets and experts armed with a profound knowledge of how business is done across the globe.
Read more
Positive final Phase I results
The final results from the Phase I clinical for our neuropathic pain drug candidate PN6047, demonstrates safety and tolerability and a lack of the adverse effects commonly associated with conventional opioids. The findings from the Phase I trial show that PN6047 is safe and well-tolerated at the doses tested, with no serious adverse events reported.
Read more